Prognostic Analysis of Patients with Primary Extranodal Lymphoma: A Retrospective Study
Received 30 December 2020
Accepted for publication 17 February 2021
Published 2 March 2021 Volume 2021:13 Pages 2171—2180
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Chien-Feng Li
Hanying Shen,1 Lingling Jiang,1 Linlin Nie,1 Xiaohui Fan,1 Yanqiu Xu,1 Lingling Yin,2 Linyan Xu,1,3 Jieyun Xia,2 Zhenyu Li,1– 3 Feng Zhu,1– 3 Kailin Xu1– 3
1Blood Disease Institute, Xuzhou Medical University, Xuzhou, Jiangsu, 221000, People’s Republic of China; 2Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221002, People’s Republic of China; 3Key Laboratory of Bone Marrow Stem Cell, Xuzhou, Jiangsu, 221000, People’s Republic of China
Correspondence: Feng Zhu; Jieyun Xia
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, 99, West Huaihai Road, Quanshan District, Xuzhou, Jiangsu, 221002, People’s Republic of China
Tel +86 516 8580 6985
Fax +86 516 8580 1527
Email [email protected]; [email protected]
Background: Originating from extranodal organs or tissues, primary extranodal lymphoma (PENL) acts in different primary sites with diverse clinical performances and PENL has remarkable geographical differences and lacks the relevant reports in each region.
Patients and Methods: Two hundred and twenty PENL patients were enrolled, and the relevant clinical and laboratory indicators were analyzed. In addition, statistical methods were applied to analyze the effects of different factors on overall survival (OS) and progression-free survival (PFS) of patients.
Results: The three most frequent primary sites of PENL are the digestive system, head and neck, and central nervous system. The patients were classified into groups based on their risk status, resulting in low-risk, medium-low-risk, medium-high-risk, and high-risk, and their respective 3-year OS values were calculated, which showed that 121 patients (55%) were in the low-risk group and 3-year OS was 85.2% (25.9% medium-low-risk, 3-year OS 66.6%; 15% medium-high-risk, 3-year OS 61.9%; 4.09% high risk, 3-year OS 45.7%). A multivariate analysis of the Cox regression demonstrated that serum beta 2-microglobulin (β2-MG) and lactate dehydrogenase (LDH) were independent prognostic factors for OS and PFS, respectively. Both the performance status and pathological subtypes were independent prognostic factors for OS and PFS.
Conclusion: The correlated independent risk factors such as β2-MG, LDH, performance status, and pathological subtypes, were helpful for effectively determining the prognosis of PENL patients and guiding treatment.
Keywords: beta 2-microglobulin, lactate dehydrogenase, performance status, pathological subtype, primary extranodal lymphoma, prognostic analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]